📱 Send Us a Text Message! We’d love to hear from you! Please include your name and email address so we can reply. Don’t worry — this won’t sign you up for our email list. We’ll only use your info to respond to your question.

Dr. Komal Patil-Sisodia explains that headlines claiming “FDA approves peptides” are misleading: an FDA advisory committee narrowly voted to recommend adding six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax) to a compounding list, a step that is not FDA approval and still faces a formal FDA process. She notes FDA scientists opposed adding all six and that some voting members sell these peptides.

Reviewing the evidence, she explains that BPC-157 has only three small, weak human studies; TB-500 has zero human trials for the injury uses it's marketed for (while full thymosin beta-4 has some real human data); KPV has no human studies at all; MOTS-c has an unpublished Phase 1b trial and only observational, exercise-related human data; Epitalon lacks Western peer-reviewed human trials; and Semax is approved in Russia but with limited-quality stroke data.

She emphasizes that all six are synthetic despite being marketed as "natural," that marketing to midlife women is running well ahead of the evidence, that contamination and mislabeled dosing have been documented in online peptide products, that compounded drugs bypass typical FDA review, and that proven options already exist for symptoms like hot flashes, bone loss, and metabolic changes.

Time Stamps:

00:00  Welcome to Clearly Hormonal

01:03  The FDA Vote Explained

03:09  BPC-157 Evidence Check

04:31  TB-500 vs. Thymosin Beta-4

06:01  KPV and Animal Data Limits

07:25  MOTS-c, Epitalon, Semax

11:32  Midlife Marketing Reality

13:37  What the List Means

14:23  Safety and Contamination Risks

16:06  Bottom Line and Next Steps

17:31  Wrap Up and Where to Follow

Resources & Mentions

• Follow Dr. Patil-Sisodia on Instagram and TikTok: @drpatilsisodia
• JAMA: “Under FDA, Unapproved Peptides Likely to Become More Widely Available” (Rita Rubin, MA, 2026)
• ABC News: “FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?” (July 24, 2026)
• Talanta (2018): impurity analysis of falsified peptide drugs seized from online pharmacies
• Expert Opinion on Drug Safety (2026): FAERS pharmacovigilance study on compounded GLP-1 receptor agonists
• Journal of Cellular and Molecular Medicine (2021): Phase I dose-escalation trial of recombinant human thymosin beta-4
• Zhurnal Nevrologii I Psikhiatrii (2018): Semax post-stroke rehabilitation study

Thanks for listening. Find more info about Clearly Hormonal on the website or Instagram.